BEAM Dec 2024 20.000 call
| Previous close | 7.60 |
| Open | 7.60 |
| Bid | 6.50 |
| Ask | 10.40 |
| Strike | 20.00 |
| Expiry date | 2024-12-20 |
| Day's range | 7.60 - 7.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 41 |
GlobeNewswireBeam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines in a poster presentation at the European Hematology Association (EHA) Hybrid Congress. The optimized process is deployed for the manufacturing of BEAM-10
ZacksWhy Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be
